+

WO2008108257A1 - 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 - Google Patents

癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 Download PDF

Info

Publication number
WO2008108257A1
WO2008108257A1 PCT/JP2008/053469 JP2008053469W WO2008108257A1 WO 2008108257 A1 WO2008108257 A1 WO 2008108257A1 JP 2008053469 W JP2008053469 W JP 2008053469W WO 2008108257 A1 WO2008108257 A1 WO 2008108257A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
cell receptor
specific
cancer antigen
peptide encoded
Prior art date
Application number
PCT/JP2008/053469
Other languages
English (en)
French (fr)
Inventor
Haruo Sugiyama
Original Assignee
International Institute Of Cancer Immunology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08720964A priority Critical patent/EP2116596A4/en
Priority to KR1020157023123A priority patent/KR101773690B1/ko
Priority to CA002679045A priority patent/CA2679045A1/en
Priority to BRPI0808341-0A2A priority patent/BRPI0808341A2/pt
Priority to MX2009009589A priority patent/MX2009009589A/es
Priority to CN2008800134367A priority patent/CN101668853B/zh
Priority to US12/529,701 priority patent/US10093977B2/en
Priority to KR1020177023678A priority patent/KR101900639B1/ko
Priority to AU2008222061A priority patent/AU2008222061B2/en
Application filed by International Institute Of Cancer Immunology, Inc. filed Critical International Institute Of Cancer Immunology, Inc.
Priority to KR1020097018554A priority patent/KR101669279B1/ko
Priority to MX2014010820A priority patent/MX343633B/es
Priority to JP2009502541A priority patent/JP5808079B2/ja
Priority to EP19150097.4A priority patent/EP3492590A3/en
Publication of WO2008108257A1 publication Critical patent/WO2008108257A1/ja
Priority to US14/184,979 priority patent/US10669584B2/en
Priority to US14/184,816 priority patent/US20140315758A1/en
Priority to US16/857,005 priority patent/US20210017599A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

　本発明は、ＷＴ１蛋白に対するＷＴ１特異的細胞傷害性Ｔ細胞（ＣＴＬ）のＴ細胞レセプター（ＴＣＲ）遺伝子のＣＤＲ３領域のヌクレオチド配列およびアミノ酸配列を提供する。また本発明は、これらのヌクレオチド配列、アミノ酸配列を用いる癌の検査や癌治療の方法、これらのヌクレオチド配列、アミノ酸配列を含む癌の検査のためのチップ、プライマーセット、キット、装置等も提供する。
PCT/JP2008/053469 2007-03-05 2008-02-28 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 WO2008108257A1 (ja)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2008222061A AU2008222061B2 (en) 2007-03-05 2008-02-28 Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
CA002679045A CA2679045A1 (en) 2007-03-05 2008-02-28 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
BRPI0808341-0A2A BRPI0808341A2 (pt) 2007-03-05 2008-02-28 Gene do receptor de célula t específico para antígeno de câncer, peptídeo codificado pelo gene e uso dos mesmos
MX2009009589A MX2009009589A (es) 2007-03-05 2008-02-28 Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
CN2008800134367A CN101668853B (zh) 2007-03-05 2008-02-28 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
US12/529,701 US10093977B2 (en) 2007-03-05 2008-02-28 Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
KR1020177023678A KR101900639B1 (ko) 2007-03-05 2008-02-28 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
EP08720964A EP2116596A4 (en) 2007-03-05 2008-02-28 L-CELL RECEPTOR GENE SPECIFIC TO A CANCER ANTIGEN, PEPTIDE CODED BY THE GENE AND THEIR USE
KR1020097018554A KR101669279B1 (ko) 2007-03-05 2008-02-28 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
KR1020157023123A KR101773690B1 (ko) 2007-03-05 2008-02-28 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
MX2014010820A MX343633B (es) 2007-03-05 2008-02-28 Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
JP2009502541A JP5808079B2 (ja) 2007-03-05 2008-02-28 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
EP19150097.4A EP3492590A3 (en) 2007-03-05 2008-02-28 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
US14/184,979 US10669584B2 (en) 2007-03-05 2014-02-20 Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US14/184,816 US20140315758A1 (en) 2007-03-05 2014-02-20 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
US16/857,005 US20210017599A1 (en) 2007-03-05 2020-04-23 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-054215 2007-03-05
JP2007054215 2007-03-05

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/529,701 A-371-Of-International US10093977B2 (en) 2007-03-05 2008-02-28 Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US14/184,979 Division US10669584B2 (en) 2007-03-05 2014-02-20 Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US14/184,816 Continuation US20140315758A1 (en) 2007-03-05 2014-02-20 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them

Publications (1)

Publication Number Publication Date
WO2008108257A1 true WO2008108257A1 (ja) 2008-09-12

Family

ID=39738141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053469 WO2008108257A1 (ja) 2007-03-05 2008-02-28 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用

Country Status (11)

Country Link
US (4) US10093977B2 (ja)
EP (4) EP3173480A3 (ja)
JP (3) JP5808079B2 (ja)
KR (3) KR101773690B1 (ja)
CN (2) CN103374576A (ja)
AU (1) AU2008222061B2 (ja)
BR (1) BRPI0808341A2 (ja)
CA (1) CA2679045A1 (ja)
MX (2) MX343633B (ja)
TW (2) TWI615469B (ja)
WO (1) WO2008108257A1 (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059804A3 (en) * 2007-11-05 2009-09-03 Medinnova As T-cell receptor peptides specific for part of cd20, uses thereof, and methods of preparing cytotoxic t-cells
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
WO2014007266A1 (ja) * 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
WO2014042226A1 (ja) * 2012-09-12 2014-03-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
JP2014143982A (ja) * 2013-01-30 2014-08-14 Igaku Seibutsugaku Kenkyusho:Kk Ｔ細胞レセプターおよびその利用
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
WO2020127357A1 (en) * 2018-12-18 2020-06-25 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
WO2022012280A1 (zh) * 2020-07-11 2022-01-20 成都益安博生物技术有限公司 一种肺癌的外周血tcr标志物及其检测试剂盒和应用
JP2022513390A (ja) * 2018-10-31 2022-02-07 オスペダーレ サン ラファエレ エス．アール．エル Ｔｃｒ及びペプチド

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2071028E (pt) 2003-11-05 2012-04-10 Int Inst Cancer Immunology Inc Péptido antigénico de ligação a hla-dr derivado de wt1
SG177998A1 (en) 2007-02-27 2012-02-28 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
HUE025636T2 (en) * 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
KR102171794B1 (ko) 2010-10-05 2020-10-29 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013166343A2 (en) * 2012-05-04 2013-11-07 Nuclea Biotechnologies, Inc. Mrm-ms signature assay
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
AR094026A1 (es) 2012-12-17 2015-07-08 Otsuka Pharma Co Ltd Metodo para activar la celula t helper
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
AU2015249371B2 (en) * 2014-04-24 2020-04-30 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
TWI726920B (zh) 2015-10-14 2021-05-11 耶魯大學 基因體規模的ｔ細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途
EP3538113A4 (en) 2016-11-14 2020-08-19 Fred Hutchinson Cancer Research Center HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN SPECIFIC TCRs AND THEIR USES
CA3055983A1 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof
WO2018231958A1 (en) * 2017-06-13 2018-12-20 Adaptive Biotechnologies Corp. Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs)
DE102017114737A1 (de) * 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
WO2019139972A1 (en) * 2018-01-09 2019-07-18 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
US20210252057A1 (en) * 2018-05-16 2021-08-19 Fred Hutchinson Cancer Research Center Merkel cell polyomavirus t antigen-specific tcrs and uses thereof
US12134637B2 (en) * 2018-07-12 2024-11-05 Bgi Shenzhen MART-1(27-35) epitope-specific T cell receptor
CN111116754A (zh) * 2018-10-30 2020-05-08 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性tcr及其应用
CN113286815B (zh) * 2018-11-09 2024-04-26 弗雷德哈钦森癌症中心 间皮素特异性t细胞受体及其在免疫治疗中的应用
US20220251167A1 (en) * 2019-06-21 2022-08-11 St. Jude Children's Research Hospital, Inc. T-Cell Receptor for Treating Fibrolamellar Hepatocellular Carcinoma
WO2021217077A1 (en) * 2020-04-24 2021-10-28 The Board Of Trustees Of The Leland Stanford Junior University Novel t-cell specificities and uses thereof
CN113092761A (zh) * 2021-03-15 2021-07-09 成都益安博生物技术有限公司 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用
CN113109564A (zh) * 2021-03-15 2021-07-13 成都益安博生物技术有限公司 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用
KR20240004935A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Prame에 특이적으로 결합하는 항원 결합 단백질
WO2024092265A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof
WO2024129720A2 (en) * 2022-12-13 2024-06-20 Biontech Us Inc. T cell receptor constructs and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) * 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
EP0602178A4 (en) 1991-08-28 1995-10-25 Wistar Inst T cell receptor-based therapy for rheumatoid arthritis.
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
US20060134641A1 (en) * 1992-05-22 2006-06-22 Franklin Richard L Treating viral infections with krill enzymes
US5494794A (en) * 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
US5672509A (en) * 1993-08-25 1997-09-30 Pfizer Inc. hPDE IV-C: a human phosphodiesterase IV isozyme
ATE298887T1 (de) 1996-04-16 2005-07-15 Kishimoto Tadamitsu Verfahren zum nachweis solider krebszellen und histologischer heterotypien und verfahren zur prüfung von gewebe für die knochenmarktransplantation und die transplantation von peripheren blutstammzellen
US5942422A (en) * 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
GB9710820D0 (en) * 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) * 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
WO1999027957A1 (en) * 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
US6090593A (en) * 1998-05-13 2000-07-18 The United States Of America As Represented By The Secretary Of The Air Force Isolation of expressed genes in microorganisms
CA2327314A1 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
HUP0202574A2 (en) 1999-02-23 2002-12-28 Baylor College Medicine T cell receptor vbetha-dbetha-jbetha sequence and methods for its detection
EP1287357A2 (en) 2000-06-02 2003-03-05 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
ATE383375T1 (de) 2001-03-22 2008-01-15 Int Inst Cancer Immunology Inc Wti-modifiziertes peptid
JP4229832B2 (ja) 2001-06-29 2009-02-25 忠範 真弓 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原とカチオン性リポソームとを含んで成る癌ワクチン
US20060035291A1 (en) 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
EP1447092A4 (en) 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
WO2003059155A2 (en) 2002-01-09 2003-07-24 Maxx Genetech Co. Ltd Method of detecting t-cell proliferation for diagnosis of diseases by gene array
US7214492B1 (en) * 2002-04-24 2007-05-08 The University Of North Carolina At Greensboro Nucleic acid arrays to monitor water and other ecosystems
KR101050703B1 (ko) 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
AU2003262094A1 (en) 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
WO2004063706A2 (en) * 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
ES2378156T3 (es) * 2003-06-27 2012-04-09 International Institute Of Cancer Immunology, Inc. Método para seleccionar pacientes adecuados para vacuna de WT1
WO2005037868A2 (en) * 2003-10-16 2005-04-28 Case Western Reserve University Methods of treating nfat-related disorders
PT2071028E (pt) 2003-11-05 2012-04-10 Int Inst Cancer Immunology Inc Péptido antigénico de ligação a hla-dr derivado de wt1
WO2005053603A2 (en) 2003-12-08 2005-06-16 Yeda Research And Development Co. Ltd. Antigen receptor variable region typing
US7576183B2 (en) * 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
JP4886507B2 (ja) 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
COULIE PG. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 10290 - 10295
DIETRICH PY. ET AL., CANCER RES., vol. 61, 2001, pages 2047 - 2054
FARINA C. ET AL.: "Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens", INT. IMMUNOL., vol. 8, no. 9, 1996, pages 1463 - 1466, XP008115108 *
GODELAINE D. ET AL., J. IMMUNOL., vol. 171, 2003, pages 4893 - 4897
KATO T. ET AL.: "Analysis of accumulated T cell clonotypes in patients with systemic lupus erythematosus", ARTHRITIS RHEUM., vol. 43, no. 12, 2000, pages 2712 - 2721, XP008115102 *
MANDRUZZATO S. ET AL., J. IMMUNOL., vol. 169, 2002, pages 4017 - 4024
OKA Y. ET AL.: "Induction of WT1 (Wilm's tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression", PROC. NATL. ACAD. SCI. U.S.A., vol. 101, no. 38, 2004, pages 13885 - 13890, XP002391406 *
OKA Y. ET AL.: "Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis", INT. J. HEMATOL., vol. 78, no. 1, 2003, pages 56 - 61, XP008115139 *
O'KEFE C.L. ET AL.: "Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses", J. IMMUNOL., vol. 172, no. 3, 2004, pages 1960 - 1969, XP008115103 *
See also references of EP2116596A4
VALMORI D. ET AL., J. IMMUNOL., vol. 168, 2002, pages 4231 - 4240

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
WO2009059804A3 (en) * 2007-11-05 2009-09-03 Medinnova As T-cell receptor peptides specific for part of cd20, uses thereof, and methods of preparing cytotoxic t-cells
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
US10648036B2 (en) 2011-06-28 2020-05-12 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
JPWO2013002086A1 (ja) * 2011-06-28 2015-02-23 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
EP3447140A2 (en) 2011-06-28 2019-02-27 International Institute of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
JP2017046698A (ja) * 2011-06-28 2017-03-09 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
WO2014007266A1 (ja) * 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
JPWO2014007266A1 (ja) * 2012-07-02 2016-06-02 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
JP2018143247A (ja) * 2012-09-12 2018-09-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
US11091531B2 (en) 2012-09-12 2021-08-17 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
JPWO2014042226A1 (ja) * 2012-09-12 2016-08-18 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
US20160009781A1 (en) 2012-09-12 2016-01-14 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
US10815288B2 (en) 2012-09-12 2020-10-27 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
WO2014042226A1 (ja) * 2012-09-12 2014-03-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
JP2014143982A (ja) * 2013-01-30 2014-08-14 Igaku Seibutsugaku Kenkyusho:Kk Ｔ細胞レセプターおよびその利用
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
JP2022513390A (ja) * 2018-10-31 2022-02-07 オスペダーレ サン ラファエレ エス．アール．エル Ｔｃｒ及びペプチド
WO2020127357A1 (en) * 2018-12-18 2020-06-25 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN113166228A (zh) * 2018-12-18 2021-07-23 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 用于治疗b细胞恶性肿瘤的cd22特异性t细胞受体和过继性t细胞疗法
JP2022514320A (ja) * 2018-12-18 2022-02-10 マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト Ｃｄ２２特異的なｔ細胞受容体およびｂ細胞悪性腫瘍の処置のための養子ｔ細胞療法
JP7570640B2 (ja) 2018-12-18 2024-10-22 マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト Ｃｄ２２特異的なｔ細胞受容体およびｂ細胞悪性腫瘍の処置のための養子ｔ細胞療法
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
WO2022012280A1 (zh) * 2020-07-11 2022-01-20 成都益安博生物技术有限公司 一种肺癌的外周血tcr标志物及其检测试剂盒和应用

Also Published As

Publication number Publication date
BRPI0808341A2 (pt) 2014-07-01
US20100190163A1 (en) 2010-07-29
AU2008222061A1 (en) 2008-09-12
EP2857508A2 (en) 2015-04-08
AU2008222061B2 (en) 2014-03-20
JP2014176382A (ja) 2014-09-25
US10669584B2 (en) 2020-06-02
EP3173480A3 (en) 2017-08-16
MX2009009589A (es) 2009-09-21
KR101900639B1 (ko) 2018-09-19
KR101669279B1 (ko) 2016-10-26
CN103374576A (zh) 2013-10-30
US20210017599A1 (en) 2021-01-21
US20140315758A1 (en) 2014-10-23
KR20090127273A (ko) 2009-12-10
EP2116596A4 (en) 2010-04-07
KR20150103385A (ko) 2015-09-10
US10093977B2 (en) 2018-10-09
TW200844225A (en) 2008-11-16
JP5808079B2 (ja) 2015-11-10
CA2679045A1 (en) 2008-09-12
MX343633B (es) 2016-11-11
EP3492590A2 (en) 2019-06-05
JP6268129B2 (ja) 2018-01-24
JP2016005466A (ja) 2016-01-14
TW201514299A (zh) 2015-04-16
CN101668853A (zh) 2010-03-10
EP2116596A1 (en) 2009-11-11
CN101668853B (zh) 2013-07-31
TWI615469B (zh) 2018-02-21
KR101773690B1 (ko) 2017-08-31
TWI615470B (zh) 2018-02-21
EP3492590A3 (en) 2019-06-19
JP5832572B2 (ja) 2015-12-16
EP2857508A3 (en) 2015-04-15
US20140315735A1 (en) 2014-10-23
KR20170101317A (ko) 2017-09-05
JPWO2008108257A1 (ja) 2010-06-17
EP3173480A2 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
WO2008108257A1 (ja) 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
EP3447140A3 (en) Receptor gene for peptide cancer antigen-specific t cell
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
WO2008089053A3 (en) Gp100-specific t cell receptors and related materials and methods of use
EP4282878A3 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
WO2009042570A3 (en) Modified t cell receptors and related materials and methods
WO2005003298A3 (en) Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease
WO2008011120A3 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2008061213A3 (en) Genetic variations associated with tumors
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2009015284A3 (en) Il-18 receptor antigen binding proteins
WO2008120998A3 (en) Acoustically sensitive drug delivery particles
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2008093280A8 (en) Anti-idiotype monoclonal antibodies as mimotopes of the hiv gp120 antigen
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
JP2015524788A5 (ja)
WO2009066462A1 (ja) 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
WO2009049966A3 (en) Methods and tools for prognosis of cancer in her2+ patients
WO2008070325A3 (en) Genetic variations associated with tumors
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
JP2021502110A5 (ja)
WO2006047728A3 (en) Bmp gene and fusion protein

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013436.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720964

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008222061

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2679045

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2008720964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008720964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5152/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009502541

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097018554

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009589

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008222061

Country of ref document: AU

Date of ref document: 20080228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12529701

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0808341

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090908

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载